ResMed Inc. (RMD)
NYSE: RMD · Real-Time Price · USD
205.17
-8.18 (-3.83%)
At close: Apr 4, 2025, 4:00 PM
193.58
-11.59 (-5.65%)
After-hours: Apr 4, 2025, 8:00 PM EDT
ResMed Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for ResMed stock have an average target of 253.88, with a low estimate of 180 and a high estimate of 286. The average target predicts an increase of 23.74% from the current stock price of 205.17.
Analyst Consensus: Buy
* Price targets were last updated on Mar 5, 2025.
Analyst Ratings
The average analyst rating for ResMed stock from 11 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 2 |
| Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Hold | 5 | 6 | 6 | 6 | 5 | 5 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 12 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Hold → Strong Buy Upgrades n/a | Hold → Strong Buy | Upgrades | n/a | n/a | Mar 5, 2025 |
| Stifel | Stifel | Hold Maintains $250 → $240 | Hold | Maintains | $250 → $240 | +16.98% | Mar 5, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $270 → $286 | Buy | Maintains | $270 → $286 | +39.40% | Jan 31, 2025 |
| Keybanc | Keybanc | Buy Maintains $266 → $280 | Buy | Maintains | $266 → $280 | +36.47% | Jan 31, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $252 → $260 | Hold | Maintains | $252 → $260 | +26.72% | Jan 31, 2025 |
Financial Forecast
Revenue This Year
5.16B
from 4.69B
Increased by 10.07%
Revenue Next Year
5.54B
from 5.16B
Increased by 7.35%
EPS This Year
9.54
from 6.92
Increased by 37.84%
EPS Next Year
10.51
from 9.54
Increased by 10.19%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.4B | 5.9B | 6.4B | ||
| Avg | 5.2B | 5.5B | 5.9B | ||
| Low | 5.0B | 5.3B | 5.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 16.0% | 13.5% | 15.4% | ||
| Avg | 10.1% | 7.3% | 7.2% | ||
| Low | 5.8% | 2.0% | 1.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.08 | 11.43 | 12.96 | ||
| Avg | 9.54 | 10.51 | 11.42 | ||
| Low | 9.10 | 9.92 | 10.38 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 45.7% | 19.9% | 23.3% | ||
| Avg | 37.8% | 10.2% | 8.7% | ||
| Low | 31.6% | 4.0% | -1.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.